Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects Against Lethal Dengue Virus Encephalitis

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1990 Sep 1

PMID 2143542

Citations 75

Authors

B Falgout

M Bray

J J Schlesinger

C J Lai

Affiliations

Soon will be listed here.

Abstract

The protective immunity conferred by a set of recombinant vaccinia viruses containing the entire coding sequence of dengue virus type 4 nonstructural glycoprotein NS1 plus various flanking sequences was evaluated by using a mouse encephalitis model. Mice immunized with recombinant vNS1-NS2a, which expresses authentic NS1, were solidly protected against intracerebral dengue virus challenge. However, mice immunized with recombinants vNS1-15%NS2a and vRSVG/NS1-15%NS2a, which express aberrant forms of NS1, were only partially protected (63 to 67% survival rate). Serologic analysis showed that mice immunized with vNS1-NS2a developed high titers of antibodies to NS1 as measured by radioimmunoprecipitation, enzyme-linked immunosorbent assay, and complement-mediated cytolytic assays. In addition, a pool of sera from these animals was protective in a passive transfer experiment. Lower titers of NS1-specific antibodies were detected in sera of animals immunized with vNS1-15%NS2a or vRSVG/NS1-15%NS2a by all three assays. These data support the view that protection against dengue virus infection in mice may be mediated at least in part by NS1-specific antibodies through a mechanism of complement-mediated lysis of infected cells. Additionally, immunization with two recombinant viruses expressing authentic NS1 of dengue virus type 2 conferred partial protection (30-50%) against dengue virus type 2 challenge.

Citing Articles

Kinetics of NS1 and anti-NS1 IgG following dengue infection reveals likely early formation of immune complexes in secondary infected patients.

Muller D, Choo J, McElnea C, Duyen H, Wills B, Young P Sci Rep. 2025; 15(1):6684.

PMID: 39994315 PMC: 11850851. DOI: 10.1038/s41598-025-91099-5.

Approaches of dengue control: vaccine strategies and future aspects.

Akter R, Tasneem F, Das S, Soma M, Georgakopoulos-Soares I, Juthi R Front Immunol. 2024; 15:1362780.

PMID: 38487527 PMC: 10937410. DOI: 10.3389/fimmu.2024.1362780.

Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections.

Sootichote R, Puangmanee W, Benjathummarak S, Kowaboot S, Yamanaka A, Boonnak K Biomedicines. 2023; 11(1).

PMID: 36672734 PMC: 9855337. DOI: 10.3390/biomedicines11010227.

Nonstructural Proteins: The Role in Molecular Mechanisms of Triggering Inflammation.

Latanova A, Starodubova E, Karpov V Viruses. 2022; 14(8).

PMID: 36016430 PMC: 9414172. DOI: 10.3390/v14081808.

Cross-reactive antibodies targeting surface-exposed non-structural protein 1 (NS1) of dengue virus-infected cells recognize epitopes on the spaghetti loop of the β-ladder domain.

Kraivong R, Traewachiwiphak S, Nilchan N, Tangthawornchaikul N, Pornmun N, Poraha R PLoS One. 2022; 17(5):e0266136.

PMID: 35617160 PMC: 9135231. DOI: 10.1371/journal.pone.0266136.

References

Cardiff R, Lund J . Distribution of dengue-2 antigens by electron immunocytochemistry. Infect Immun. 1976; 13(6):1699-709. PMC: 420822. DOI: 10.1128/iai.13.6.1699-1709.1976. View

Joklik W . The preparation and characteristics of highly purified radioactively labelled poxvirus. Biochim Biophys Acta. 1962; 61:290-301. DOI: 10.1016/0926-6550(62)90091-9. View

Halstead S, ORourke E . Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977; 265(5596):739-41. DOI: 10.1038/265739a0. View

Halstead S, ORourke E . Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977; 146(1):201-17. PMC: 2180729. DOI: 10.1084/jem.146.1.201. View

Halstead S, ORourke E, Allison A . Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med. 1977; 146(1):218-29. PMC: 2180735. DOI: 10.1084/jem.146.1.218. View

Henchal E, Gentry M, McCown J, BRANDT W . Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg. 1982; 31(4):830-6. DOI: 10.4269/ajtmh.1982.31.830. View

Smith G, Wright P . Synthesis of proteins and glycoproteins in dengue type 2 virus-infected vero and Aedes albopictus cells. J Gen Virol. 1985; 66 ( Pt 3):559-71. DOI: 10.1099/0022-1317-66-3-559. View

Wertz G, Collins P, Huang Y, Gruber C, Levine S, Ball L . Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A. 1985; 82(12):4075-9. PMC: 397937. DOI: 10.1073/pnas.82.12.4075. View

Schlesinger J, Brandriss M, Walsh E . Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol. 1985; 135(4):2805-9. View

10.

Satake M, Coligan J, Elango N, Norrby E, Venkatesan S . Respiratory syncytial virus envelope glycoprotein (G) has a novel structure. Nucleic Acids Res. 1985; 13(21):7795-812. PMC: 322087. DOI: 10.1093/nar/13.21.7795. View

11.

Gould E, Buckley A, Barrett A, Cammack N . Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol. 1986; 67 ( Pt 3):591-5. DOI: 10.1099/0022-1317-67-3-591. View

12.

Chakrabarti S, Brechling K, Moss B . Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol. 1985; 5(12):3403-9. PMC: 369169. DOI: 10.1128/mcb.5.12.3403-3409.1985. View

13.

Henchal E, Henchal L, Thaisomboonsuk B . Topological mapping of unique epitopes on the dengue-2 virus NS1 protein using monoclonal antibodies. J Gen Virol. 1987; 68 ( Pt 3):845-51. DOI: 10.1099/0022-1317-68-3-845. View

14.

Schlesinger J, Brandriss M, Walsh E . Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol. 1987; 68 ( Pt 3):853-7. DOI: 10.1099/0022-1317-68-3-853. View

15.

Kaufman B, Summers P, Dubois D, Eckels K . Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg. 1987; 36(2):427-34. DOI: 10.4269/ajtmh.1987.36.427. View

16.

Zhao B, Prince G, Horswood R, Eckels K, Summers P, CHANOCK R . Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J Virol. 1987; 61(12):4019-22. PMC: 256024. DOI: 10.1128/JVI.61.12.4019-4022.1987. View

17.

Hahn Y, Galler R, Hunkapiller T, Dalrymple J, Strauss J, Strauss E . Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses. Virology. 1988; 162(1):167-80. DOI: 10.1016/0042-6822(88)90406-0. View

18.

Halstead S . Pathogenesis of dengue: challenges to molecular biology. Science. 1988; 239(4839):476-81. DOI: 10.1126/science.3277268. View

19.

Vijaya S, Elango N, Zavala F, Moss B . Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein. Mol Cell Biol. 1988; 8(4):1709-14. PMC: 363331. DOI: 10.1128/mcb.8.4.1709-1714.1988. View

20.

Cane P, Gould E . Reduction of yellow fever virus mouse neurovirulence by immunization with a bacterially synthesized non-structural protein (NS1) fragment. J Gen Virol. 1988; 69 ( Pt 6):1241-6. DOI: 10.1099/0022-1317-69-6-1241. View